Your SlideShare is downloading. ×
0
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Vesiculo bullous II
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Vesiculo bullous II

1,076

Published on

Oral Pathology I …

Oral Pathology I
Third Year

Published in: Health & Medicine, Technology
0 Comments
8 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,076
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
8
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Vesiculo-Bollous Diseases 2 Aiman A. Ali, DDS, PhD. Associate Professor, Oral Pathology & Medicine College of Dentistry, King Faisal University
  • 2. Vesiculo-Bollous Diseases Viral  Associated with immunologic defects  Hereditary  Aiman A. Ali DDS, PhD.
  • 3. Vesiculo-Bollous Diseases 2 Associated with immunologic defects Pemphigus Vulgaris Cicatricial pemphigoid Bullous pemphigoid Dermatitis herpetiformis Linear IgA Disease Aiman A. Ali DDS, PhD. Hereditary Epidermolysis Bullosa
  • 4. Pemphigus Vulgaris Aiman A. Ali DDS, PhD.
  • 5. Etiology  Reactive IgG against epithelial desmosometonofilament complexes  Loss of cell-to-cell adherence (acantholysis) Pemphigus antibody + Target antigen Activate epithelial intracellular protolytic enzyme Desmosome-tonofilament complex Aiman A. Ali DDS, PhD. Acantholysis
  • 6. Clinically  Mucocutaneuos disease  Skin lesions appear after OL in a period of 1 year  Ulcers preceded by bullae  60% of cases the first appearance in the oral cavity  More common in the 4th and 5th decade  Nikolsky sign is positive Aiman A. Ali DDS, PhD.
  • 7. Aiman A. Ali DDS, PhD.
  • 8. Clinically Aiman A. Ali DDS, PhD.
  • 9. Histopathologically  Acantholysis  Tzanck cells [free-floating rounded or spherical SSC]  Basal layer remains attached to the basement membrane  Bulla or vesicle are filled with fluid, Tzanck cells and neutrophils Aiman A. Ali DDS, PhD.
  • 10. Aiman A. Ali DDS, PhD.
  • 11. Tzanck cells Aiman A. Ali DDS, PhD.
  • 12. Aiman A. Ali DDS, PhD.
  • 13. Aiman A. Ali DDS, PhD.
  • 14. Immunofluorescence Direct Aiman A. Ali DDS, PhD. Indirect
  • 15. Indirect Immunofluorescence Appear in 80% of Pemphigus Vulgaris patients To assess the severity of the lesion Aiman A. Ali DDS, PhD.
  • 16. Aiman A. Ali DDS, PhD.
  • 17. Aiman A. Ali DDS, PhD.
  • 18. Aiman A. Ali DDS, PhD.
  • 19. Differential diagnosis  Pemphigoid  Erythema (bullous or cicatricial) multiform  Bullous lichen planus  Dermatitis herpetiformis  Paraneoplastic pemphigus  In syndrome small lesions, aphthous stomatitis Aiman A. Ali DDS, PhD.
  • 20. Pemphigus vegetans  Skin, vermilion and oral mucosa  Histopathologically: epithelial hyperplasia with intraepithelial abscess formation  Abundant eosinophils Aiman A. Ali DDS, PhD.
  • 21. Aiman A. Ali DDS, PhD.
  • 22. Treatment  High dose of corticosteroids  Immunosuppressant agents to reduce complications of SAIDs as (osteoporosis, hyperglycemia, hypertension)  When SAIDs are contraindicated Gold therapy is recommended Aiman A. Ali DDS, PhD.
  • 23. Paraneoplastic Pemphigus  Simulate pemphigus vulgaris clinically  Associated with lymphoma or other malignancies  Histopathologically and IF is different Aiman A. Ali DDS, PhD.
  • 24. Cicatricial Pemphigoid Aiman A. Ali DDS, PhD.
  • 25. Etiology  Benign mucous membrane pemphigoid, ocular pemphigus, childhood pemphigoid, and mucosal pemphigoid  Idiopathic autoimmune disease  Deposit of IG and complement components along the basement zone  Usually no circulating antibodies Aiman A. Ali DDS, PhD.
  • 26. { { { { { {
  • 27. Clinical features  More common among adult women  Chronic lesions appear as vesiculo-bullous eruptions involve oral mucosa, which heal with scaring  When affects gingiva exclusively is referred to as gingivosis or desquamative gingivitis  Other sites: conjunctiva, larynx, genitalia, and esophagus  Skin lesions are uncommon  Nikolsky’s sign is positive Aiman A. Ali DDS, PhD.
  • 28. Histopathology  Sub-basal clefting with clear cut separation at the basement membrane  No evidence of acantholysis  Variable infiltration with lymphocytes, plasma cells and occasionally eosinoand neutrophils  Blood vessels often are dilated Aiman A. Ali DDS, PhD.
  • 29. Aiman A. Ali DDS, PhD.
  • 30. Aiman A. Ali DDS, PhD.
  • 31. Immunofluorescence  Direct IF of intact oral mucosa demonstrate linear pattern of IgG fluorescence  Occasionally IgA may detected  Complement components are commonly found  Indirect IF studies are usually negative Aiman A. Ali DDS, PhD.
  • 32. Aiman A. Ali DDS, PhD.
  • 33. Aiman A. Ali DDS, PhD.
  • 34. Aiman A. Ali DDS, PhD.
  • 35. Differential diagnosis Pemphigus vulgaris Erosive lichen planus Aiman A. Ali DDS, PhD.
  • 36. Aiman A. Ali DDS, PhD.
  • 37. Treatment  Topical corticosteroids (betamethasone dexamethasone…etc)  In severe cases systemic SAIDs with immunosuppressive agents Aiman A. Ali DDS, PhD.
  • 38. Aiman A. Ali DDS, PhD.
  • 39. Bullous pemphigoid Aiman A. Ali DDS, PhD.
  • 40. Etiology  Similar to cicatricial pemphigoid  There are circulating autoantibodies to basement membrane zone antigen  Degeneration of basement membrane attachment complexes  Separation occur at the lamina lucida plane
  • 41. Clinical features  Very common in the 7th and 8th decades  Lesions affect the skin
  • 42. Histopathology  Normal HP the same of CP  Ultrastructurally: the basement membrane is cleaved at the level of lamina lucida
  • 43. Immunopathology  There is a detectable level of circulating antibodies in 70% of cases  However, no correlation with the level of clinical disease  IF findings corresponding to those in CP
  • 44. Treatment  Systemic corticosteroids
  • 45. Dermatitis herpetiformis
  • 46. Etiology  Unknown cause  Deposits of  No IgA in the skin and mucosa circulating autoantibodies in the patient’s serum
  • 47. Clinical features  Chronic disease typically seen in young adults  Cutaneous disease, rarely appear in the oral cavity  Symmetrical aggregated vesicular lesions of the skin with face and scalp involvement  Periods of exacerbation and remission  Iodide component exacerbate some cases  Orally lesions appear as superficial ulcers with fibrinous base preceded by vesicles
  • 48. Histopathology  Accumulation of neutrophils and eosinophils producing dermal micro-abscess  Connective tissue become necrotic and the overlying epithelium separate  Formation of subepithelial vesicle
  • 49. Immunopathology  Immunofluorescent staining is positive at the epidermal-dermal junction  Almost IgA alone or in combination with IgG or IgM
  • 50. Treatment  It dose not respond to SAIDs  Sulfapyridine is the  Gluten-free diet treatment of choice
  • 51. Linear IgA Disease
  • 52.  IgA deposits at the dermal-epidermal junction in linear pattern  Not associated with gluten-sensitive enteropathy  Common oral lesions  Separation at the basement membrane
  • 53. Epidermolysis Bullosa
  • 54. Etiology  Hereditary disease  In one type acquired  Formation of blisters at sites of minor trauma
  • 55. Clinical features  Muco-Cutaneous disease  It has several different forms:  EB Simplex  EB dystrophic dominant  EB dystrophic recessive (Oral Manifestations)  Junctional EB  EB Acquista  Very common in • Hereditary (newborns and early childhood) • Acquired (adulthood)
  • 56. Treatment Symptomatic
  • 57. { { { { { {

×